Ajovy Webcast Summary
Dr. Susan Hutchinson joined Dr. Jack Schim for a live Webcast on Thursday evening, October 25th, to discuss Ajovy, the second CGRP monoclonal Antibody approved for migraine prevention. It is an injection and offers the option of quarterly or monthly dosing. Results can be seen as early as 1 week in some patients. This new category of CGRP monoclonal antibodies is target specific for migraine, very tolerated, and highly effective for most migraine sufferers. An exciting time in history with this break-through treatment for migraine prevention.